Jeff Boyd, PhD
Senior Vice President, Molecular Medicine
Robert C. Young, MD, Chair in Cancer Research
Executive Director, Cancer Genome Institute
Chief, Division of Molecular Pathology
Professor, Cancer Biology Program
Dr. Boyd is an international expert in translational research and has particular expertise in the genetics of breast, ovarian and endometrial cancer. He has helped define the role of tumor suppressors and oncogenes in these malignancies, most notably the p53, BRCA1 and BRCA2 tumor suppressor genes and their role in the development of breast and ovarian cancer.
Karen S Gustafson, MD, PhD
Chief Medical Officer, Cancer Genome Institute
Director, Molecular Diagnostics Laboratory
Dr. Gustafson's research interests are in the areas of cancer genetics/epigenetics and molecular biomarker development using both tissue and cytologic samples. Specific research efforts have focused on defining DNA methylation profiles in HPV-associated cervical carcinogenesis. The Keystone Programs in Epigenetics and Stem Cell Progenitors and Personalized Risk and Prevention at Fox Chase offer unique opportunities for research collaborations.
Biao Luo, PhD
Laboratory Director, Cancer Genome Institute,
Assistant Research Professor, Cancer Biology Program
Dr. Luo's areas of research include: 1) systematic identification of genetic alterations in cancer patients by high-throughput sequencing, 2) investigation of oncogenic networks perturbed by these genetic alterations with high-throughput functional screens. By deepening our understanding of cancer genetics, this research will contribute to developing clinical trials with new therapies and matching emerging drug treatments to the unique genetics of individual patient tumors.
Anthony J Olszanski, MD, RPh
Senior Medical Advisor, Cancer Genome Institute
Director, Early Clinical Development Phase 1 Program
Associate Professor, Developmental Therapeutics Program
Dr. Olszanski's research focus is principally aimed at developing new drugs through collaborations with investigators, cooperative groups, and pharmaceutical companies. His greatest interest lies in early drug development (Phase 1 Research Trials) using molecularly targeted small molecules or antibodies in cancer. Through the collaborative efforts of the Developmental Therapeutics Program he focuses on the development of biomarkers to help define the optimal patient population who will benefit from a new drug.
Eric A. Ross, PhD
Assistant Vice President, Biometrics and Information Sciences
Associate Professor, Cancer Prevention and Control Program
Director, Biostatistics and Bioinformatics Facility
Director, Population Studies Facility
Dr. Ross' research interests include clinical trials design and analysis, correlated survival analysis, longitudinal data modeling, population informatics and facilitation of biomedical research through data warehousing.